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1. Introduction
  Osteoporosis is a major health problem, the prevalence 
of osteoporosis increases with age. Overall, it is estimated 
that 50% of women and 25% of men aged more than 50 years 
will have osteoporosis-related fracture in their remaining 
lifetime[1]. Due to aging population in the world, the 
osteoporosis-related fractures have been a great problem in 
the world[2,3]. According to the World Health Organization 
data, osteoporosis affects approximately 75 million 
people throughout Europe, the US, and Japan[1]. In the US 
osteoporosis occurs in 55% of the population aged 50 years 
and above[2]. It is estimated that the number of women and 
men with osteoporosis would increase from 44 million to 
more than 61 million by 2020 in the America and the annual 
fractures and associated costs in the United States will 
increase by nearly 50%[2]. Likewise, worldwide projections 
of the incidence of hip fracture indicate that it will increase 
by 240% in women and 310% in men between 1990 and 
2050[4]. The primary health burden imposed by osteoporosis 
is increased risk for bone fractures and the health cost. 
Fractures are usually associated with disability, reduced 
quality of life, increased risk of subsequent fractures, and 
also are related to higher mortality and high health care 
costs[2,3].
  Oral nitrogen-containing bisphosphonates are standard 
treatment for osteoporosis[5], which could inhibit farnesyl 
diphosphate synthase, a key branch point of the mevalonate 
pathway, and inhibit protein prenylation in osteoclasts[6]. 
These nitrogen-containing bisphosphonates could induce 
bisphosphonates potent inhibitors of bone resorption 
and remodeling activity[7]. Zoledronic acid (ZOL) is an 
intravenous, nitrogen-containing bisphosphonate with 
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a prolonged dosing interval and the potential to increase 
patient compliance with bisphosphonate therapy and 
thereby to improve patient outcomes. ZOL 5 mg has been 
approved by the Food and Drug Administration for the 
treatment of postmenopausal osteoporosis, treatment 
of male osteoporosis, and treatment and prevention of 
glucocorticoid-induced osteoporosis as a once-yearly 
infusion. It is also approved for prevention of osteoporosis 
in postmenopausal women as an infusion given once every 
2 years[8]. However, the clinical evidence in the effect of 
ZOL on osteoporosis and its complication is conflicting. 
Therefore, we conducted a meta-analysis regarding the 
published randomized controlled clinical trials of ZOL in 
treatment and prevention of osteoporosis.
2. Materials and methods
2.1. Literature search
  The Medline, EMbase and Pubmed were selected with the 
use of dozens of complex search strategies containing index 
terms. The data of the last search was April 2012. The best 
search strategy for each database that resulted in the most 
relevant randomized clinical trials was used in the final 
analysis (Figure 1). A total of 729 articles were identified, 
9 randomized clinical trials regarding ZOL on osteoporosis 
were included finally.
Potential relevant studies
(n=729)
Excluding experim ental or unrelated 
studies (n=620)
S t u d i e s  r e g a r d i n g  Z O L  o n 
osteoporosis (n=109)
Excluding studies with duplicated data, 
reviews of unrelated data (n=80)
Full text regarding ZOL on 
osteoporosis (n=29)
Excluding studies with data unable 
to exact (n=20)
S tud ies  inc luded  in  our 
analysis (n=9)
Figure 1. Flow chart of retrieving studies.
 
2.2. Study selection
  Studies were included in our study were according to the 
following criteria: Firstly, the studies should be a comparison 
studies about ZOL supplements vs. placebo. Secondly, 
studies should report the clinical outcome of the effects of 
ZOL on the bone markers; Thirdly, the duplicated reports 
of the studies were excluded. Randomization by clusters 
or individuals were acceptable. We used no language or 
publication status restrictions. 
  Two researchers independently reviewed the title, abstract 
and conclusion of studies according to the inclusion and 
exclusion criteria of the relevant randomized clinical trials. 
If there was disagreement, consensus was resolved by 
discussion.
2.3. Data extraction
  Data on year, county, study design, number of participants, 
intervention, and outcomes for bone markers were also 
independently extracted by two reviewers and were 
confirmed by each other. If necessary, data on outcomes 
for bone markers were obtained from graphs reported. If 
possible, we obtained necessary data which has not been 
reported by contacting the authors.
2.4. Statistical analysis
  We performed a meta-analysis to determine the overall 
treatment effect of ZOL on bone markers, using RevMan 
software for all of the statistical analysis. The treatment 
effect of the included studies was estimated by the mean 
difference between the changes from baseline of bone 
marker to the makers after intervention. We used both a 
fixed effect model or a random effects model to calculate 
the weighted mean differences with 95% CIs for each 
comparison, a combined overall effect with P value, and 
the P value for testing heterogeneity (P<0.1 was considered 
significant). When there was significant heterogeneity across 
the included trials, a random effects model was used to 
analysis. The I2 statistic was calculated by the percentage of 
I2. 0% to 40% showed no heterogeneity; 30% to 60% showed 
moderate heterogeneity; 50% to 90% showed substantial 
heterogeneity; and 75% to 100% showed great heterogeneity 
across studies. Funnel plot was taken to evaluate publication 
bias. Subgroup analysis and meta-regressions were 
performed to investigate possible factors that might relate to 
varying effects of ZOL on each bone markers across trials, 
on the basis of menopausal status, ZOL and intervention 
duration.
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Table 1 
Characteristics of the studies included in the meta-analysis.
Study ID Country Follow-
up(months)
Samples
(Intervention/
controls)
Age(years) Sex Outcomes Adverse effect
Black
 2012[9]
USA 36-72 451/470 75.5
Men 
& women
BMD, fracture 
27.27% serious adverse 
effect in ZOL, 31.16% in 
control 
Boonen
 2011[10]
Belgium 12-24 250/248 72.6 Women BMD, fracture
42.0% serious adverse effect 
in ZOL, 46.0% in control
Sambrook
 2012[11]
USA 12 88/177 57.2 Women BMD No serious adverse effect
B o o n e n 
2010[12]
Belgium 36 1 961/1 926 >75 Women BMD, fracture
25.6% serious adverse effect 
in ZOL, 27.4% in control
Hwang
 2011[13]
China 36 163/160 72.5依0.4 Women BMD, fracture
20.2% serious adverse effect 
in ZOL, and 32.7% in control
Bubbear
 2011[14]
T h e  U n i t e d 
Kingdom
12 7/7 28.6依14.4
9 men 
& 5 women
BMD No serious adverse effect
Black
 2007[15]
The United State 36 3 889/3 879 73.0依5.4 Women BMD fracture
30.1% serious adverse effect 
in ZOL, and 29.2% in control
Kenneth
 2007[16]
Holland 20 1 961/1 926 >50 
24.5% men 
&  7 5 . 5 % 
women
Fracture
38.3% serious adverse effect 
in ZOL, and 41.2% in control
Ian 2002[17] New Zealand 12 59/59 45-80 Women BMD
76% serious adverse effect 
in ZOL, and 86% in control
3. Results
  A total of 9 trials included in this meta-analysis (Table 
1). Data for follow-up durations were ranged from 1 year 
to 6 years. In the included studies, participants in the 
comparison group had the similar demographics data 
with the control group. Most of the included studies were 
conducted in Western counties, only one study conducted in 
China. There were 8 studies regarding the outcome of bone 
mineral density (BMD), and 5 studies regarding the outcome 
of fracture. Most of the studies were conducted in female 
patients due to the high incidence of osteoporosis in females. 
The rate of serious adverse effect in ZOL intervention group 
was at the range of 20%-86%.
  Figure 2 showed the effect of intravenous ZOL on the BMD 
among participants. The random effects model was used 
and revealed that the BMD among experimental participants 
was significantly higher than the controls. The pooled effect 
showed the ZOL could increase the BMD by 2.98 times 
compared with placebo, which indicated the ZOL could 
significantly increase the BMD among participants. Figure 
3 showed that the role of ZOL in the fracture of participants. 
There was no significant heterogeneity among studies, and 
the I2 was 29% (I2=95%). All trials showed the ZOL could 
decrease the rate of fracture, and the pooled results showed 
the fracture in patients could be significantly reduced by 
32%.
  Moreover, analysis of the serious adverse effect of ZOL was 
shown in Figure 4. The results revealed the ZOL intervention 
had significantly less serious adverse effect than control, 
and the odds ratio was 0.81 (0.76-0.87). A significantly 
heterogeneity was found between studies. Most of the 
serious adverse effects were renal diseases, pyrexia and 
cardiovascular or cerebrovascular problems. 
  Subgroup analysis regarding the participants age and 
intervention duration time was also performed. Participants 
aged 50 years showed better effect of ZOL on osteoporosis, 
including higher BMD value and lower risk of fracture. 
Moreover, the longer term intervention, more than 12 
months intervention, could gain a better prevention effect 
on osteoporosis (OR, 95% CI for BMD was 3.35, 2.77-3.92; 
for fracture was 0.67, 0.54-0.82) (Table 2 and Table 3). The 
funnel plots did not show an obvious publication bias (Figure 
5 and Figure 6).
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Figure 3. Effect of intravenous ZOL on the fracture.
Study of subgroup
Experimental Control Odds ratio
M-H, Random, 95% CI
Odds ratio
M-H, Random, 95% CIEvents Total Events Total Weight
Balck 2012 14 451 27 470 5.7% 0.53 (0.27, 1.02)
Boonen 2010 50 1 961 70 1 926 15.4% 0.69 (0.48, 1.00)
Boonen 2011 92 1 062 139 1 065 23.2% 0.63 (0.48, 0.83)
Kenneth 2007 91 1 065 148 1 062 23.4% 0.58 (0.44, 0.76)
Black 2007 165 3 889 196 3 876 32.2% 0.83 (0.67, 1.03)
Total (95% CI) 8 428 8 399 100.0% 0.68 (0.58, 0.80)
Heterogeneity: Tau2=0.01; Ch2=5.64, df=4 (P=0.23); I2=29%
Test for overall effect: Z=4.63 (P<0.0001)
0.5         0.7            1                1.5        2
Favours experimental Favours control
Study of subgroup
Experimental Control Odds ratio
M-H, Fixed, 95% CI
Odds ratio
M-H, Fixed, 95% CIEvents Total Events Total Weight
Balck 2012    123 451 146    470   5.2% 0.83 (0.63, 1.11)
Black 2007 1 171 3 889 1 133 3 879 39.3% 1.04 (0.95, 1.15)
Boonen 2010    502 1 961    528 1 926 19.6% 0.91 (0.79, 1.05)
Boonen 2011    105    250    114    248   3.3% 0.85 (0.60, 1.21)
Bubbear 2011       0        7        0        7 Not estimable
Hwang 2011     33    162     52   160   2.1% 0.53 (0.32, 0.88)
Ian 2002     45     59     51     59   0.6% 0.50 (0.19, 1.31)
Kenneth 2007    480 1 961   794 1 926 30.0% 0.46 (0.40, 0.53)
Sambrook 2012        0     88       0    177 Not estimable
Total (95% CI) 8 828 8 852 100.0% 0.81 (0.76, 0.87)
Total events 2 459 2 818
Heterogeneity: Ch2=96.72, df=6 (P<0.0001); I2=94%
Test for overall effect: Z=6.26 (P<0.00001)
0.5         0.7             1                1.5         2
Favours experimental Favours control
Figure 4. Serious adverse effect of intravenous ZOL on osteoporosis.
Study of subgroup
Experimental Control Std. mean difference
桇. Random. 95% CI
Std. mean difference
桇. Random. 95% CIMean SD Total Mean SD Total Weight
Balck 2012 1.49 0.21    451 0.95 0.18    470 13.0% 2.76 (2.58, 2.94)
Black 2007 1.36 0.14 3 889 0.79 0.14 3 879 13.1% 4.06 (3.98, 4.14)
Boonen 2010 4.98 0.98 1 961 1.98 0.54 1 926 13.1% 3.78 (3.68, 3.89)
Boonen 2011 2.70 0.34   250 1.90 0.23    248 12.9% 2.78 (2.50, 3.00)
Bubbear 2011 1.19 0.80       7 1.08 0.50        7 10.3% 0.15 (0.90, 1.20)
Hwang 2011 0.51 0.01  163 0.47 0.01    160 12.0% 7.58 (6.95, 8.21)
lan 2002 0.95 0.10    59 0.88 0.08      59 12.7% 0.77 (0.39, 1.14)
Sambrook 2012 4.91 1.21    88 3.20 0.87    177 12.9% 1.71 (1.42, 2.01)
Total (95% CI) 6 868 6 926 100.0% 2.98 (2.26, 3.71)
Heterogeneity: Tau2=1.03; Ch2=842.78, df=7 (P<0.0001); I2=99%
Test for overall effect: Z=8.12 (P<0.0001)
-10         -5             0               5            10
Favours experimental Favours control
Figure 2. Effect of intravenous ZOL on the BMD.
Table 2 
Subgroup analysis of ZOL on the BMD.
Variables Trials Sample size P value for heterogeneity
BMD
OR 95%  CI
Age (years) ≤50 2 66/66 0.28 0.67 0.22, 1.11
>50 6 6 802/6 860 <0.05 3.71 3.02, 4.40
Intervention duration (months) ≤12 4 317/403 0.08 2.56 0.04, 5.16
>12 7 6 551/6 523 <0.05 3.35 2.77, 3.92
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Figure 5. Funnel plot of role of ZOL on BMD.
 
0
0.1
0.2
0.3
0.4
0.5
0.5                          0.7                             1                                 1.5                       2
OR
SE (log [OR] )
Figure 6. Funnel plot of role of ZOL on fracture.
 
4. Discussion
  This meta-analysis showed that ZOL had better effect on 
treatment of osteoporosis. These finding provide evidence 
for the efficacy of ZOL in improving the BMD and reducing 
the fracture among patients with osteoporosis. 
  Previously, biosphosphonates are the preferred medications 
used for osteoporosis treatment and act by inhibiting 
osteoclastic activity. Previous studies reported that these 
drugs could greatly reduce the incidence of hip, vertebral 
and non-vertebral fracture by 50%[18,19]. However, the 
unsatisfied absorption of intestinal limited the use of these 
drugs. Intravenous ZOL could be better absorbed and be 
administered as once-yearly 5-mg intravenous infusion 
over no less than 15 minutes[20]. Our study pooled 9 studies, 
and showed a significantly higher BMD of ZOL intervention 
group than controls, and only one study with small sample 
showed the ZOL could not increase the BMD[14]. Recently a 
guideline recommend that the pharmacological therapy be 
considered for postmenopausal women with osteoporosis 
and for women without osteoporosis at moderate to high 
fracture risk, based on a combination of BMD and clinical 
risk factors[21]. In our study, we found that the ZOL could 
improve the BMD in individuals, especially increase higher 
BMD in high risk of osteoporosis, which showed the ZOL 
could be an effective way in treatment of osteoporosis and 
has a favorable role in preventing fracture. Furthermore, the 
heterogeneity between studies showed there might be other 
factors which influence the effect of ZOL on osteoporosis. 
After the subgroup analysis regarding the age and 
intervention duration, the heterogeneity was greatly reduced, 
but there was still significant heterogeneity between studies. 
Therefore, some factors such as baseline characteristics of 
patients, such as BMI, BMD of the baseline, ethnicities, etc 
should be considered. 
  The safety profile in the ZOL group is better than 
controls. Lower risk of serious adverse effect was found 
in ZOL intervention group than the placebo, such as only 
calcium and vitamine D, or hormone therapy, raloxifene, 
calcitonin or tibolone along with calcium and vitamin D. The 
appropriateness and safety of pharmacological therapy in 
treatment of osteoporosis has been extensively debated[22-25]. 
Our study provides sufficient evidence for the safety of ZOL 
by pooling several large sample randomized clinical trials.
  There were some limitations in our study. Firstly, there is 
still great heterogeneity between studies even after subgroup 
analysis, which indicated further analysis regarding 
influencing factors should be considered. Secondly, few 
numbers of studies included in our analysis would limit 
the statistic power, and therefore, we should performed 
subgroup analysis regarding the location of BMD or fracture 
of participants by ZOL intervention. 
  In conclusion, this present study showed the ZOL could 
be effective approach in the prevention of osteoporosis, and 
Table 3 
Subgroup analysis of ZOL on the fracture.
Variables Trials Sample size P value for heterogeneity
BMD
OR 95% CI
Age (years) ≤50 1 30/35 - 0.15 0.03, 1.03
>50 4 8 398/8 364 0.07 0.68 0.59, 0.89
Intervention duration (months) ≤12 1 1 961/1926 - 0.67 0.22, 1.11
>12 4 6 467/6 473 0.13 0.67 0.54, 0.82
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could increase the BMD and reduce the risk of facture.
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